Headspace Health Announces Acquisition of AI-Driven Mental Health and Wellness Company, Sayana
12.1.2022 16:50:00 EET | Business Wire | Press release
Headspace Health, the provider of the world’s most accessible, comprehensive digital mental health platform, today announced the acquisition of Sayana, an AI-driven mental health and wellness company. Sayana will expand Headspace Health’s ability to provide personalized self-care content to its growing global member base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005244/en/
Headspace Health announces acquisition of AI-driven mental health and wellness company, Sayana.
Founded in 2018 and backed by Y Combinator in 2020, Sayana has supported users around the world to improve their mental wellness by helping its members become more mindful of the connections between their feelings and events. The Sayana Self-Care app leverages chat-based sessions with an AI persona named Sayana, who encourages users to track their mood along with what influences it. Sayana personalizes users’ experiences based on their check-ins and mood trends, surfacing high-quality content and self-care exercises rooted in cognitive behavioral therapy (CBT), acceptance commitment therapy (ACT) and dialectical behavioral therapy (DBT), as well as breathing exercises. In addition, the Sayana Sleep app helps members to enjoy deep and restful sleep sessions sequenced based on their mood and sleep patterns.
“Amidst a rapidly growing landscape of mental health and wellness apps, Sayana has developed a uniquely engaging member experience backed by world-class AI and machine learning algorithms,” said Russell Glass, CEO, Headspace Health. “Sayana's technology, and most importantly, Sayana’s team, will help us meaningfully advance our product and content strategy as we continue to build the world’s most comprehensive mental health and wellbeing platform.”
On the heels of its recent merger between Headspace and Ginger, Headspace Health is creating an integrated experience to tackle the full spectrum of mental health needs - from prevention to clinical care - all from one platform backed by AI and data science. Today, Ginger leverages AI to support its team of behavioral health coaches, therapists and psychiatrists to ensure quality interactions with members, comprehensive tracking of services, and close collaboration among care providers. Headspace harnesses the power of AI to surface and recommend content in order to foster healthy habit formation. With the addition of Sayana, Headspace Health will advance its capability to personalize member experiences - to better understand, support and improve their feelings and mood.
Sayana founder and CEO Sergey Fayfer will join Headspace Health and take on a product leadership role, along with an experienced team of engineers and designers who will further advance the company’s unique and engaging member experiences.
“Since our inception, we’ve been on a mission at Sayana to put self-care in everyone’s pocket,” said Sergey Fayfer, Founder and CEO of Sayana. “We’re thrilled to bring together our technology, engineering and design expertise to help advance Headspace Health’s efforts to democratize high-quality, affordable mental healthcare around the world.”
The terms of the deal were not disclosed.
About Headspace Health
Headspace Health is the world’s leading provider of mental health and wellbeing solutions. Through our flagship Headspace brand, we’ve touched the lives of over 100 million people in 190 countries through mindfulness tools for managing stress, sleep, and focus. Our enterprise brands, Headspace for Work and Ginger, are distributed through over 3,500 enterprises, including Starbucks, Adobe, Delta Air Lines, and ViacomCBS; and through health plans such as Cigna. Our members and enterprise partners’ employees have access to mindfulness and meditation tools, CBT, coaching, therapy, and psychiatry, ultimately helping them to be healthier and more productive. To learn more about Headspace Health and our family of brands, visit www.headspacehealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005244/en/
Contact information
Victoria Barnes
Sr. Director, Global Communications & Corporate Marketing, Headspace Health
781 249 3738
press@headspacehealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom